Technological offer

Novel peptide-based compounds for the treatment of cardiovascular diseases, including ventricular arrhythmias in patients with heart failure and hereditary syndromes characterized by reduced function of sodium or potassium ion channels.

An in vitro screening method by NMR spectroscopy of potential therapeutic compounds for Congenital Central Hypoventilation Syndrome (CCHS). The method is based in the identification of active agents that inhibit secondary structure changes in PHOX2B transcription factor.

An in vitro fluorescent method for early detection of  Amyotrophic Lateral Sclerosis (ALS) and other TDP-43 related proteinopathies, such as Fronto Temporal Lobar Degeneration (FTLD), based on detection of pathological aggregates of TDP-43 present in cerebrospinal fluid.

Analysis of TAF1 isoforms in blood and cerebrospinal fluid of controls and individuals with Multiple Sclerosis.

Natural nutraceutical to promote the prevention of the cancer stem cells (CSCs) phenotype acquisition at the origin of tumor regrowth, metastasis and relapse.

Stratum corneum lipid-matrix like liposomes capable of acting as oral mucosa impermeabilization agents to prevent the penetration of viruses or biocides through the mucosa.

New nanostructured lipid carriers have demonstrated inhibition of bacterial biofilm formation. They are useful for treating or preventing chronic infections such as those associated with prosthetic implants and recurrent respiratory infections.

Novel glycolipid mimetics able to express anti-inflammatory or adjuvant activity in a context dependent manner. The compounds can be used for the treatment of immune diseases cursed with Th1/Th2 imbalance or as vaccine adjuvants.

A new immunotherapy strategy based on the administration of a monoclonal antibody specific for pre-TCR has been developed and validated in a preclinical human T-ALL xenotransplantation model in mice.

Inhibitor of Interferon type I (IFN-I) is capable of inhibiting the inflammatory response in those autoimmune diseases in which this cytokine is involved, called interferonopathies, such as systemic lupus erythematosus and Aicardi-Goutières syndrome.